Intracellular survival of Leishmania species that cause visceral Leishmaniasis is significantly reduced by HIV-1 protease inhibitors

Journal of Infectious Diseases

Volumn 198, Issue 9, 2008, Pages 1292-1299

  Trudel, Nathalie ^a   Garg, Ravendra ^a   Messier, Nadine ^a   Sundar, Shyam ^b   Ouellette, Marc ^a   Tremblay, Michel J ^a  

^a LAVAL UNIVERSITY   (Canada)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

NELFINAVIR; RITONAVIR; SAQUINAVIR; STIBOGLUCONATE SODIUM;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GROWTH INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; MACROPHAGE; NONHUMAN; PARASITE SURVIVAL; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

EID: 54249094595     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/592280     Document Type: Article

References (35)

1. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:334-59.
2. Zhao C, Papadopoulou B, Tremblay MJ. Leishmania infantum enhances human immunodeficiency virus type-1 replication in primary human macrophages through a complex cytokine network. Clin Immunol 2004; 113:81-8.
3. Zhao C, Thibault S, Messier N, Ouellette M, Papadopoulou B, Tremblay MJ. In primary human monocyte-derived macrophages exposed to human immunodeficiency virus type 1, does the increased intracellular growth of Leishmania infantum rely on its enhanced uptake? J Gen Virol 2006; 87:1295-302.
4. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10:298-319.
5. Olivier M, Badaro R, Medrano FJ, Moreno J. The pathogenesis of Leishmania/ HIV co-infection: cellular and immunological mechanisms. Ann Trop Med Parasitol 2003; 97(Suppl 1):79-98.
6. Fillola G, Corberand JX, Laharrague PF, Levenes H, Massip P, Recco P. Peripheral intramonocytic leishmanias in an AIDS patient. J Clin Microbiol 1992; 30:3284-5.
7. Martinez P, de la Vega E, Laguna F, et al. Diagnosis of visceral leishmaniasis in HIV-infected individuals using peripheral blood smears. AIDS 1993; 7:227-30.
8. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277:145-53.
9. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 2005; 49:2983-5.
10. Andrews KT, Fairlie DP, Madala PK, et al. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother 2006; 50:639-48.
11. Savarino A, Lucia MB, Rastrelli E, et al. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 2004; 35:223-32.
12. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008; 46:1702-9.
13. Savoia D, Allice T, Tovo PA. Antileishmanial activity of HIV protease inhibitors. Int J Antimicrob Agents 2005; 26:92-4.
14. Roy G, Dumas C, Sereno D, et al. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol 2000; 110:195-206.
15. Sereno D, Cavaleyra M, Zemzoumi K, Maquaire S, Ouaissi A, Lemesre JL. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother 1998; 42:3097-102.
16. Lira R, Sundar S, Makharia A, et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999; 180:564-7.
17. Vergnes B, Gourbal B, Girard I, Sundar S, Drummelsmith J, Ouellette M. A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics 2007; 6:88-101.
18. +-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol 2002; 76:1004-14.
19. Natera S, Machuca C, Padron-Nieves M, Romero A, Diaz E, Ponte-Sucre A. Leishmania spp.: proficiency of drug-resistant parasites. Int J Antimicrob Agents 2007; 29:637-42.
20. Barat C, Zhao C, Ouellette M, Tremblay MJ. HIV-1 replication is stimulated by sodium stibogluconate, the therapeutic mainstay in the treatment of leishmaniasis. J Infect Dis 2007; 195:236-45.
21. Robertson CD. The Leishmania mexicana proteasome. Mol Biochem Parasitol 1999; 103:49-60.
22. Kayser O, Kiderlen AF, Bertels S, Siems K. Antileishmanial activities of aphidicolin and its semisynthetic derivatives. Antimicrob Agents Chemother 2001; 45:288-92.
23. Burchmore RJ, Barrett MP. Life in vacuoles: nutrient acquisition by Leishmania amastigotes. Int J Parasitol 2001; 31:1311-20.
24. Valiathan R, Dubey ML, Mahajan RC, Malla N. Leishmania donovani: effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Indian clinical isolates to sodium stibogluconate. Exp Parasitol 2006; 114:103-8.
25. Brochu C, Wang J, Roy G, et al. Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimonyresistant parasites. Antimicrob Agents Chemother 2003; 47:3073-9.
26. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19:111-26.
27. Mukherjee A, Padmanabhan PK, Singh S, et al. Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J Antimicrob Chemother 2007; 59:204-11.
28. Legare D, Richard D, Mukhopadhyay R, et al. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J Biol Chem 2001; 276:26301-7.
29. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37:3594-601.
30. Srinivas RV, Middlemas D, Flynn P, Fridland A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998; 42:3157-62.
31. Jones K, Hoggard PG, Sales SD, Khoo S, Davey R, Back DJ. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001; 15:675-81.
32. Tovo PA. Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects. AIDS 2000; 14:743-4.
33. Andre P, Groettrup M, Klenerman P, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998; 95:13120-4.
34. Gaedicke S, Firat-Geier E, Constantiniu O, et al. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 2002; 62:6901-8.
35. Nathoo S, Serghides L, Kain KC. Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. Lancet 2003; 362:1039-41.